Zhi Tong Cai Jing·2026-02-06 12:45Core Viewpoint - China Resources Pharmaceutical (03320) reported that China Resources Sanjiu (000999) achieved a total revenue of approximately 31.629 billion yuan in 2025, representing a year-on-year increase of 14.53% [1] - The net profit attributable to shareholders of the listed company was approximately 3.422 billion yuan, reflecting a year-on-year growth of 1.6% [1] - The basic earnings per share stood at 2.06 yuan [1] Group 1 - In 2025, China Resources Sanjiu faced challenges such as a decrease in the incidence of respiratory diseases like influenza and ongoing medical insurance cost control [1] - The company is committed to a strategic direction focused on "innovation + brand" dual-driven approach to navigate the complex market environment [1] - China Resources Sanjiu is concentrating on core therapeutic areas, expanding its research and development pipeline from multiple dimensions to uncover innovative value [1] Group 2 - The company is enhancing its brand advantages and continuously optimizing its business layout to forge a competitive edge across the entire industry chain [1] - China Resources Sanjiu aims to solidify its leading position in the industry and is making steady progress towards its strategic goal of becoming a top-tier enterprise in the sector [1]